Drugs for opioid use disorder.

IF 1.4 4区医学 Q4 PHARMACOLOGY & PHARMACY

Medical Letter on Drugs and Therapeutics Pub Date : 2023-09-04 DOI:10.58347/tml.2023.1684a

引用次数: 0

Abstract

Opioid use disorder is a chronic, relapsing disease with physical and psychiatric components. It is associated with economic hardship, social isolation, incarceration, increased rates of blood-borne infections such as HIV and viral hepatitis, adverse pregnancy outcomes, and increased mortality. According to the NIH, there were 80,411 deaths involving an opioid in the US in 2021, more than in any previous year. Several guidelines on the management of opioid use disorder are available; all recommend maintenance pharmacotherapy as the standard of care.

查看原文本刊更多论文

阿片类药物使用障碍的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Letter on Drugs and Therapeutics 医学-药学

CiteScore

1.00

自引率

42.10%

发文量

审稿时长

6-12 weeks

期刊介绍： The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry. The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides: Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings Consensus recommendations for the preferred and alternative treatments for common disorders Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.